UPDATED Jun 17, 2024
Companies with strong growth potential, backed by optimistic outlooks both from analysts and management.
Company | Last Price | 7D Return | 1Y Return | Market Cap | Analysts Target | Valuation | Growth | Div Yield | ||
---|---|---|---|---|---|---|---|---|---|---|
TBBB | US$21.58 | -6.3% | n/a | US$2.5b | US$25.66 | PB14.6x | E100.1% | n/a | ||
SEM | RM1.98 | 0% | -1.0% | RM2.2b | RM1.98 | PB5.9x | E54.1% | 1.4% | ||
RADL3 | R$25.07 | 0% | -12.6% | R$43.0b | R$30.50 | PE40.9x | E25.4% | 0.8% | ||
7687 | JP¥392.00 | 1.6% | -4.9% | JP¥2.6b | n/a | PE11.6x | E24.3% | n/a | ||
RDC | €111.90 | -3.1% | 22.3% | €2.3b | €149.42 | PS1.1x | E46.9% | n/a | ||
3034 | JP¥1,436.00 | 0.9% | -19.2% | JP¥53.4b | n/a | PE11x | E29.4% | 2.4% | ||
2791 | JP¥8,260.00 | -1.2% | 63.2% | JP¥117.3b | n/a | PE20.5x | E28.9% | 0.4% | ||
2722 | JP¥378.00 | -0.5% | 0.5% | JP¥3.0b | n/a | PB1.4x | E87.6% | 1.3% | ||
605266 | CN¥32.12 | -15.3% | -41.1% | CN¥5.0b | CN¥52.06 | PE12.7x | E21.0% | 3.3% | ||
MEDPLUS | ₹697.25 | -1.1% | -12.9% | ₹83.4b | ₹889.50 | PE127.3x | E40.4% | n/a | ||
DDL | US$1.91 | -1.5% | -42.3% | US$404.2m | US$1.97 | PB7.1x | E73.6% | n/a | ||
3549 | JP¥3,066.00 | -1.5% | 14.8% | JP¥292.8b | JP¥3,650.00 | PE33.6x | E21.6% | 0.4% | ||
241 | HK$3.39 | -10.8% | -30.0% | HK$55.5b | HK$5.35 | PE57.3x | E23.1% | n/a | ||
BESHOM | RM1.00 | -1.0% | -8.3% | RM303.0m | n/a | PE28.4x | E28.3% | 3.0% |